Immune regulation by microbiome metabolites by Kim, Chang H.
This is the author manuscript accepted for publication and has undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/imm.12930 
This article is protected by copyright. All rights reserved 
 
PROF. CHANG  KIM (Orcid ID : 0000-0003-4618-9139) 
 
 
Article type      : Review 
 
 
Immune regulation by microbiome metabolites 
 
Chang H. Kim 
 
Department of Pathology and Mary H. Weiser Food Allergy Center, University of Michigan 
Medical School, Ann Arbor, MI, USA 
 
*Correspondence: Chang Kim, Ph.D., Kenneth and Judy Betz Professor, 4025 BSRB 109, Zina 
Pitcher Place, Ann Arbor, MI  48109-2200; Phone: 734-647-6183; Email address: 
chhkim@med.umich.edu 
 
Grant support: 
 
This study was supported, in part, from grants from NIH (R01AI121302 and 
R01AI080769) to CHK.  
 
Abstract Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
Commensal microbes and the host immune system have been co-evolved for mutual regulation. 
Microbes regulate the host immune system, in part, by producing metabolites. A mounting body 
of evidence indicates that diverse microbial metabolites profoundly regulate the immune system 
via host receptors and other target molecules. Immune cells express metabolite-specific receptors 
such as P2X7
 
, GPR41, GPR43, GPR109A, aryl hydrocarbon receptor precursor (AhR), pregnane 
X receptor (PXR), farnesoid X receptor (FXR), TGR5 and other molecular targets. Microbial 
metabolites and their receptors form an extensive array of signals to respond to changes in 
nutrition, health and immunological status. As the consequence, microbial metabolite signals 
contribute to nutrient harvest from diet, and regulate host metabolism and the immune system. 
Importantly, microbial metabolites bidirectionally function to promote both tolerance and 
immunity to effectively fight infection without developing inflammatory diseases. In pathogenic 
conditions, adverse effects of microbial metabolites have been observed as well. Key immune-
regulatory functions of the metabolites, generated from carbohydrates, proteins and bile acids, 
are reviewed in this article. 
Key Words: Microbiome, Metabolites, Short-Chain Fatty Acids, Bile Acids, Indole, Immunity, 
Inflammation, Barrier Function. 
 
Introduction 
Commensal microbiota functionally maturate the host immune system. This effect is mediated 
by microbial factors that stimulate host cells. Microbial factors work through a variety of host 
receptors and molecular targets on or within host cells. Host receptors for microbial factors 
include pattern recognition receptors (PRRs) such as Toll-like receptors (TLR), nucleotide 
oligomerization receptors (NLR), C-type lectin receptors (CLR) and RIG-1 like receptors (RLR), 
which sense major microbial constituents such as DNA, RNA, proteins, and cell wall 
components. However, these microbial constituents are just a fraction of what commensal 
microbes produce to regulate the host immune system. In the alimentary tract, host enzymes 
process dietary materials, such as starch, dietary fibers, proteins/peptides, and lipids for nutrients 
harvest in the small intestine. However, some dietary materials inevitably reach the colon for 
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microbial fermentation due to incomplete digestion and absorption. These materials feed the 
microbiota for production of a variety of microbial metabolites, some of which have immune 
regulatory roles. It is thought that there are 500-1000 microbial operating taxonomic units 
(OTUs) in the mammalian gut. While each microbial species has a finite number of genes that 
code for nutrient transporters and metabolizing enzymes, the combined number of these genes 
for the whole microbiota would be enormous 1. Moreover, the microbiota employ a wide variety 
of nutrient utilizing enzymes in numbers that far exceed that of the human enzyme repertoire. 
Because the products of microbial enzymes are absorbed in the colon and utilized by the host, 
the gut microbiota increase nutrient or energy recovery from consumed diets. Microbial 
metabolites have significant effects on the host metabolism 2-4. Moreover, some of the 
metabolites also condition and activate the immune s(page 5)10ystem to increase the immune 
function but decrease harmful inflammatory responses 5-8
The concentrations of certain microbial metabolites, best exemplified by short-chain fatty 
acids (SCFAs), reach very high concentrations in the colon 
. 
9
, lowering pH, fulfilling nutritional 
needs, regulating microbial function and composition, and conditioning the immune system. 
Host cells express various receptors to sense microbial metabolites, which include purinergic 
receptors such as P2X7 to detect microbial and host-derived nucleotides (e.g. Adenosine 
Triphosphate/ATP and Nicotinamide Adenine Dinucleotide/NAD) 10; GPR43 and GPR41 to 
detect SCFAs; membrane bile acid receptor (M-BAR/TGR5) and FXR to detect bile acid and 
xenobiotic metabolites 11, 12; and AhR and PXR to detect tryptophan, indole, bile acid, and 
toxicant metabolites 13, 14
 
. Moreover, the roles of dietary factors that activate immune cells, 
including certain phytochemicals, even without microbial modifications should not be ignored. 
This article is to review our current understanding of the origin, host receptors, and target cells of 
major microbial metabolites in the immune system. Detailed impacts of these metabolites on the 
innate and adaptive arms of the immune system are discussed. 
Major groups of microbial metabolites and their receptors 
Carbohydrate metabolites: Bacteria produce SCFAs as the result of carbohydrate fermentation in 
the colon (Figure 1). Bacteria express carbohydrate-active enzymes such as glycoside hydrolases 
and polysaccharide lyases 15, 16. These enzymes often form enzyme complexes (e.g. 
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cellulosomes) to process long carbohydrate fibers into simple sugars 17. Released component 
sugars, such as glucose and xylose, are transported into bacteria via the phosphotransferase 
system for uptake and phosphorylation of carbohydrates for fermentation 18. While the human 
genome encodes 17 enzymes to breakdown carbohydrate nutrients, some gut bacteria such as 
Bacteroides thetaiotaomicron encode over 260 glycoside hydrolases 19. Because there are a few 
hundred bacterial and yeast species in the gut, the total number of carbohydrate-active enzymes 
and their overall combined capacity to handle different dietary fibers are expected to be 
sufficient to handle most of consumed polysaccharides. While both soluble and insoluble dietary 
fibers can be processed by bacteria, soluble fibers such as arabinoxylan, pectin, inulin and 
hemicellulose, are preferentially utilized to produce SCFAs in the gut over insoluble fibers such 
as cellulose and chitin 20. Also, digestion-resistant oligosaccharides, such as 
fructooligosaccharide and xylooligosaccharide, and resistant starches along with host 
glycoproteins, such as mucins, can be processed to produce SCFAs. Microbes greatly differ in 
their ability to ferment dietary fibers and sugars to produce different SCFAs. In general, 
members of the Bacteroidetes phylum are good producers of acetate (C2) and propionate (C3), 
whereas bacteria in the Firmicutes phylum are efficient butyrate (C4) producers 21. More 
specifically, Akkermansia municiphilla produces C3 from mucin 22. Roseburia inulinivorans and 
Coprococcus catus produce both C3 and C4 23-25. Faecalibacterium prausnitzii, Eubacterium 
rectale, Eubacterium hallii and Ruminococcus bromii, are good producers of C4 26. Also, 
Roseburia intestinalis, Eubacterium rectale and Clostridium symbiosum are good C4-producers 
and are increased in numbers with high fiber diet 27. Ruminococcus bromii produces C4 from 
resistant starch 28. SCFAs are absorbed by colonocytes and other cells via solute transporters and 
simple diffusion. SLC16a1 and SLC5a8 are major transporters for SCFAs 8. C4 is mainly used 
by colonocytes, whereas C2 and C3 are transported out to the portal circulation. C2 and C3 are 
transported to the liver, muscle, brain and other organs. C2 is converted into acetyl-CoA for 
lipogenesis or oxidation in peripheral muscles. Most C3 is metabolized in the liver and 
contributes to gluconeogenesis. SCFAs affect the metabolism of host cells, activating multiple 
metabolic pathways to produce energy and building blocks and regulating host metabolism 29, 30. 
Also produced by microbes are lactate and succinate, which can be converted to C3 by many 
bacterial species 31. SCFAs activate several cell surface G-protein-coupled receptors (GPRs), 
such as GPR43, GRP41, GRP109A and Olfr78 32-35. GPR43 and GRP41 are highly expressed by 
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intestinal epithelial cells 36. T and B cells do not express these SCFA receptors but certain 
myeloid cells, such as neutrophils, macrophages and dendritic cells, express GPR43 and 
GPR109A at variable levels to sense the concentration of SCFAs in tissue environments 32, 33, 37-
39
 
. 
Amino acid and related metabolites: Another abundant group of dietary materials includes 
proteins. Proteins are digested into oligopeptides and amino acids, which are largely absorbed in 
the small intestine. Some proteins, oligopeptides and amino acids, not processed or absorbed in 
the small intestine, reach the colon for bacterial catabolism and utilization. Many bacterial 
groups, including certain Clostridium, Bacillus, Lactobacillus, Streptococcus, and Proteobacteria 
groups, are effective metabolizers of proteins, causing “protein putrefaction” 40. Among amino 
acids, glycine, lysine, arginine, leucine, isoleucine and valine are preferred amino acid substrates 
for gut bacteria 41. Microbial catabolism of these amino acids generates ammonia, biogenic 
amines (monoamines and polyamines), and other metabolites. Polyamines are produced from 
ornithine, arginine, lysine and methionine 42. Decarboxylation of amino acids generates 
histamine (from histidine), agmatine (from arginine), and cadaverine (from lysine) 43. For 
example, Lactobacillus plantarum decarboxylates ornithine to produce putrescine, a major 
polyamine 44. Moreover, branched-chain SCFAs, such as isobutyrate, valerate and isovalerate, 
are produced from respective branched amino acids (i.e. leucine, valine, and isoleucine) 45
Indole is produced from tryptophan and metabolized into kynurenine, indole-3-acetic 
acid, and tryptamine. Bacterial trytophanase produces indole, and host-produced indoleamine-
pyrrole 2,3-dioxygenase (IDO) generates kynurenine. These indole metabolites activate aryl 
hydrocarbon receptor (AhR) and PXR 
. 
Similar to C4, branched-chain SCFAs are potent histone deacetylase (HDAC) inhibitors and, 
therefore, their functions in regulating host cells are expected to be similar to that of C4. The 
luminal concentrations of branched-chain SCFAs are relatively lower than those of the major 
SCFAs (C2-C4). 
46-48
. Non-protein materials such as glucobrassicin, a 
compound found in cruciferous vegetables, are metabolized to indole-3-carbinole, which also 
activates AhR 49. AhR acts as a transcription factor to induce expression of genes such as 
CYP4501A1, which detoxifies chemicals and toxins 50. 
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Lipid and bile acid metabolites: Gut bacteria produce many lipid-modifying and metabolizing 
enzymes. For example, hydroxy fatty acids are generated from polyunsaturated fatty acids by 
gastrointestinal microorganisms such as Lactobacillus plantarum, which encodes 
polyunsaturated fatty acid-saturating enzymes 51, 52. Roseburia species are active in metabolizing 
linoleic acid (cis-9,cis-12-18:2) 53. They produce vaccenic acid; a precursor of health-promoting 
linoleic acids. These fatty acid-modifying functions of the microbiota can change the lipid profile 
in the gut lumen. Bile acids are produced from the liver and secreted into the small intestine to 
emulsify triglyceride and fatty acids. Primary bile acids, such as cholic acid and 
chenodeoxycholic acid (CDCA), are produced in the gall bladder and secreted into the 
duodenum as conjugated forms to glycine and taurine. Most of the secreted bile acids are 
reabsorbed in the terminal ileum. Gut microbiota alter bile acids through various modifications, 
including hydrolysis of the C24N-acyl amide bond, oxidation and epimerization of hydroxyl 
groups, 7α-dehydroxylation, esterification, and desulfatation 54. These processes generate more 
than twenty different secondary bile acids, including deoxycholic acid (DCA) and lithocholic 
acid (LCA). Also, phosphatidylcholine is metabolized to produce important metabolites such as 
trimethylamine-N-oxide (TMAO). Gut microbes convert choline to trimethylamine, which is 
absorbed and then converted by the flavin monooxygenase system in the liver to TMAO 55. 
Other substrates of gut bacteria to produce trimethylamin include betaine (trimethylglycine) and 
carnitine (a lysine derivative). Bile acids activate many cell types through cell receptors, such as 
FXR, VDR, PXR and TGR5 (also called GP-BAR1 or M-BAR) 12, 56. FXR, VDR, and PXR are 
nuclear receptor family members, whereas TGR5 is a G-protein-coupled receptor. FXR is 
expressed by many cell types, including epithelial and endothelial cells in the liver, 
gastrointestinal tract, and kidney 57, 58. PXR is expressed by cells in the liver, small intestine, and 
colon 14, 59. TGR5 is widely expressed in the body. Its expression is particularly high in the 
intestines, pancreas, lungs, lymphoid tissues, and brain 60
 
.  
Altered microbial metabolites in diseases 
Metabolites are produced by the microbiota and, thus, changes in the microbiota or dysbiosis, 
can alter metabolite profiles. Particularly, metabolites are altered in many pathogenic conditions 
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such as obesity, type I diabetes, alcoholic and hepatitis B virus (HBV)-induced liver diseases, 
inflammatory bowel diseases, cancer and other chronic diseases. Alteration of SCFA levels 
and/or microbial producers have been observed in many diseases. It has been observed that C2 
and C3 are decreased in some patients with type I diabetes or colitis 61, 62. Similarly, C2 and C4 
levels were decreased in patients with colitis, colon cancer, or other intestinal disorders 63, 64. 
Also, low dietary fiber intake and decreased levels of SCFAs and some other longer chain fatty 
acids have been observed in allergy patients 65-67. Increased levels of C2 and C4 along with the 
expansion of Firmicutes species are associated with obesity 68. In addition, indole derivatives are 
also altered in some diseases. For example, and tryptophan metabolism seems to be increased in 
inflammatory bowel disease (IBD) patients and the levels of tryptophan metabolites such as 
kynurenine and indole-3-acetate were altered in some colitis patients 69, 70
 
. However, more data 
are needed to firmly connect the changes of specific metabolites to diseases. Assuming that these 
metabolites regulate many cell types in most parts of the body, changes in the metabolites could 
have comprehensive effects, potentially altering immune and inflammatory responses, 
metabolism, neuronal functions, cancer development, and other processes. 
Immune regulatory functions of SCFAs  
As the most abundant microbial metabolites among all in the colonic lumen, SCFAs play multi-
faceted regulatory roles in the immune system (Figure 2). First, SCFAs are used by colonocytes 
as a major energy source, and they influence gene expression necessary for epithelial barrier and 
defense functions. Second, SCFAs regulate innate immune cells such as macrophages, 
neutrophils and dendritic cells. Third, SCFAs bidirectionally regulate antigen-specific adaptive 
immunity mediated by T cells and B cells.  
Dietary fiber and SCFAs support intestinal epithelial proliferation 71, 72. SCFAs are 
converted to acetyl-CoA for energy production through the tricarboxylic acid (TCA) cycle and 
lipid synthesis 73. SCFAs also inhibit HDACs to promote gene expression in epithelial cells 74. In 
the colonic lumen, SCFAs decrease intracellular pH and facilitate sodium ion absorption through 
multiple mechanisms, mediated in part through the Na+-H+ and Cl--HCO3- exchange pumps 71, 75, 
76
. SCFAs are weak acids and play important roles in lowering pH in the gut lumen. SCFAs 
induce cancer cell differentiation and apoptosis, and, therefore, is generally perceived as tumor 
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suppresors77. This function is closely associated with the HDAC inhibition and the histone 
hyperacetylation effects of SCFAs to regulate genes that control key cellular processes 78. A 
caveat for this role is that C4 promotes hyperproliferation of mutated (MSH2-/)- colon epithelial 
cells and thus has the potential to even promote certain types of tumors 79. A function important 
for barrier immunity is the positive effects of SCFAs on epithelial cell production of certain 
cytokines such as IL-18 and antimicrobial peptides 80, 81. SCFAs also enhance the expression of 
epithelial barrier-forming molecules and mucin production, which are mediated, in part, by 
HDAC inhibition and AMP-activated protein kinase (AMPK) activation 82-85
SCFAs regulate myeloid cells. Neutrophils are the prototype myeloid cells that express 
the SCFA receptor GPR43. GPR43 activation by SCFAs induces chemotaxis and functional 
activation of neutrophils 
. 
32, 33, 37, 86
. SCFAs also regulate macrophages. C4 conditions intestinal 
macrophages through GPR109A to induce IL-10-producing T cells 87. While GPCR activation 
by SCFAs is involved in regulating macrophages, the HDAC inhibitor function of SCFAs is also 
important. For example, C4 down-regulates lipopolysaccharide-induced production of nitric 
oxide and inflammatory cytokines such as IL-6 and IL-12 in a GPCR-independent manner 
presumably through HDAC inhibition 88. C4 suppresses production of inflammatory cytokines 
such as TNF-α, MCP-1, and IL-6 in macrophages 89. SCFAs also regulate dendritic cells (DCs). 
Human monocyte-derived DCs cultured with C3 or C4 were less inflammatory with decreased 
production of pro-inflammatory cytokines and chemokines 90. It was documented that SCFAs 
also indirectly affect DCs by inducing retinaldehyde dehydrogenase 1 (RALDH1) expression in 
intestinal epithelial cells, which leads to retinoic acid (RA) production and subsequent generation 
of RA-regulated DCs with a tolerogenic phenotype 91
SCFAs can also directly and indirectly regulate T cell differentiation into functionally 
specialized cells 
. 
8
. This occurs when T cell undergo antigen priming by antigen presenting cells 
in the presence of SCFAs. It was initially reported that C4 suppresses CD4+ T cell proliferation 
but does not induce FoxP3+ T cells 92. However, several groups reported that C4 and C3 can 
increase colonic FoxP3+ Tregs in vivo and/or in vitro settings, potentially through their HDAC 
inhibitor activity 93-95. In our own study, all major SCFAs (i.e. C2, C3, and C4), enhanced the 
generation of effector T cells such as Th17 and Th1 as well as IL-10+ CD4+ T cells in both in 
vitro and in vivo settings 38. However, the number of FoxP3+ T cells was not necessarily 
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increased in vivo and in vitro, whereas the number of IL-10+ T cells was increased by SCFAs. 
However, the IL-10+ T cell-inducing effect of SCFAs is lost during active immune responses to 
C. rodentium 38
It has long been recognized that consumption of dietary fiber increases host antibody 
responses in animals 
. During active immune responses, the numbers of Th17 cells and Th1 cells were 
increased by SCFAs. Overall, SCFAs have significant impacts on regulatory T cells and effector 
T cells depending on immunological context. This is perhaps due to the booster effect of SCFAs 
on gene expression during lymphocyte activation. HDAC inhibition increases histone acetylation 
but it does not have selectivity toward Treg versus effector T cells. Rather, SCFAs have the 
tendency to boost the polarization effects set by cytokine milieus present at time of T cell 
priming and differentiation. Because SCFA levels are high in the colonic tissues and gut-
associated lymphoid tissues, intestinal T cells are likely to be a major target of SCFAs.  
96
. In vitro, C4 increased B cell production of antibodies, which was 
associated with increased histone acetylation 97. Our laboratory systematically studied the impact 
of dietary fiber and SCFAs on antibody responses to commensal bacteria and pathogens 98. 
SCFAs exert strong epigenetic regulatory effects on B cells through their HDAC inhibitory 
activity and promote B cell differentiation into plasma B cells. SCFAs can boost the production 
of both IgA and IgG isotypes. They increase IgA-coated intestinal bacteria and promote IgA and 
IgG production in response to C. rodentium infection. This indicates that both mucosal and 
systemic antibody responses are boosted by SCFAs. SCFAs up-regulate three important 
metabolic processes, such as glycolysis, oxidative phosphorylation and lipogenesis, in B cells, 
which are necessary to produce cellular building blocks and energy to support plasma B cell 
differentiation. It is believed that HDAC inhibition by SCFAs promotes histone acetylation to 
enhance gene expression necessary for plasma B cell differentiation. Another potentially 
important regulatory mechanism of SCFAs is mediated by their impact on cellular metabolism. 
SCFAs increase the levels of acetyl-CoA and ATP but decrease AMP level and AMPK activity, 
leading to increased mTOR activity that sustains the high metabolic demand of differentiating B 
cells 98
Through the effects on many cell types, SCFAs exert comprehensive regulatory effects 
on inflammatory diseases. Compared to wild type mice, GPR43
. High metabolic activity is necessary to fully support plasma B cell differentiation.  
-/- mice suffer more from dextran 
sulfate sodium (DSS)-induced colitis 99. However, GPR43 signaling promotes also acute 
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inflammatory responses required to mount normal immune responses to microbes, which is 
delayed in GPR43-/- mice 100. C4 enema has been reported to suppress chronic colitis in mice and 
humans 101, 102. However, C4 was not effective in suppressing acute colitis responses such as 
2,4,6‐trinitrobenzene  sulfonic acid (TNBS)-induced inflammation 103. SCFAs and dietary fiber 
also suppress inflammatory responses associated with type I diabetes and food allergy responses 
in animal models 104, 105. SCFAs can also suppress acute kidney injury in an animal model 106. 
However, chronic administration of SCFAs induced urethritis in mice characterized by smooth 
muscle cell and epithelial hyperplasia leading to hydronephrosis 107
 
. Therefore, SCFAs can 
promote also inflammatory responses depending on their concentrations, organs and host 
condition.  
Immune regulatory functions of amino acid and indole-related metabolites 
Major indole derivatives, generated either from tryptophan or plant-derived glucobrassicin, 
activate AhR. AhR is activated by many natural and synthetic chemicals such as indole-3-
acetate, indole-3-carbinol, kynurenine, resveratrol, indirubin, flavonoids, omeprazole, and dioxin 
(2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD). Therefore, AhR is important not only for dietary 
factor-regulated but also for environmental pollutant-modulated immune responses. Upon ligand 
binding, cytoplasmic AhR translocates to the nucleus and heterodimerizes with aryl hydrocarbon 
receptor nuclear translocator (ARNT). Dimerized AhR binds the consensus xenobiotic 
responsive element (XRE,  5′-GCGTG-3′) in many genes encoding toxicant-modifying enzymes 
or immune-regulatory molecules. The XRE is thought to be created by insertion of transposable 
elements such as LINE-1 and Alu 108. Ahr regulates many genes including the genes coding for 
CYP450 1A1, Indoleamine 2,3-dioxygenase (IDO), IL-10, Aiolos, FoxP3, IL-21, and CD39. For 
T cells, AhR activation supports Th17 but suppresses Treg differentiation 109. AhR works 
together with other transcription factors, such as STAT3, to turn on Aiolos or regulates 
STAT1 110, 111. Interestingly, AhR activation by TCDD had an opposite effect, boosting Tregs but 
suppressing Th17 cell differentiation. In this case, AhR works with another transcription factor 
c-Maf, which promotes IL-27-induced IL-10+ T cells 112. AhR activation promotes monocyte 
differentiation into DCs over macrophages 113. In vivo, dietary indoles suppress Th17 but 
increase Treg responses 114. Thus, the effects of Ahr ligands on T cell responses are complex, 
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mediated by many factors and cell types. AhR function is not necessarily equal to that of AhR 
ligands in overall immune responses. This is probably because AhR functions as a transcription 
regulator regardless of the presence of ligands and its function is further regulated by ligands. 
Moreover, different ligands and cooperating transcription factors could lead to heterogenous 
outcomes. 
 Polyamine regulate transcription, protein translation, stress protein responses, and cellular 
metabolism. They have the potential to exert regulatory functions on immune cells. Polyamines 
have anti-inflammatory effects, in part, by suppressing inflammatory T cells and the production 
of cytokines and nitric oxide (NO) 115. Blocking of polyamine synthesizing enzymes in host cells 
can break tolerogenic tumor microenvironments 116. Spermine can regulate autophagy and 
apoptosis and suppress the production of IL-12 but increase that of IL-10 117, 118. Polyamines also 
exert repair functions following tissue damages. However, the functions and mechanisms of 
actions of various polyamines in regulating the immune system remain unclear at the molecular 
level 42
 
. Particularly it remains to be determined how gut microbiota-derived polyamines are 
transported through the gut barrier and regulate immune cells. 
Immune regulatory functions of bile acid and related cholesterol metabolites 
Bile acids play important anti-inflammatory roles in cholestatic and metabolically driven 
inflammatory diseases. Low bile acid levels correlate with increased susceptibility to 
infection 119. However, chronic exposure to high levels of bile acids can induce inflammation and 
cancer 120. Secondary bile acids, such as DCA and LCA, regulate the immune system, in part, 
through their receptors, such as TGR5 (also called GPBAR1 or M-BAR) and two nuclear 
receptors, FXR and PXR. Animals deficient in TGR5 develop more severe colitis induced by T 
cell-activating haptens (TNBS and oxazolone) 121. Similarly, FXR-/- mice were more susceptible 
to TNBS-induced colitis than WT mice 122. Also, DSS-induced colitis was more severe in PXR-/-
 mice 123. These data suggest that bile acid receptors promote immune tolerance. One caveat is 
that not all the phenotype of FXR-/- mice can be attributed to the function of bile acid 
metabolites, because these receptors, particularly PXR and FXR, are activated also by non-bile 
acid metabolite ligands. Moreover, these receptors, particularly those receptors that function as 
transcription factors, can have ligand-independent regulatory functions. TGR5 ligands, such as 
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LCA and DCA, suppress TNFα production by macrophages 124. TGR5 activation induces cAMP 
production and subsequent phosphorylation of c-Fos, leading to NF-κB inhibition. In this regard, 
TGR5 ligands generate DCs that have decreased production of IL-12 125. Consistently, 
instillation of DCA into the colon exacerbated colitis responses 126, 127. Bile acid metabolites 
regulate NLRP3 inflammasome activation, but their exact roles in this regard are 
controversial 128, 129
 
. While the functions of bile acid metabolites and their functions appear to be 
complex and are probably determined by receptors, cell types, tissue sites, and immunological 
context, these metabolites play important roles in regulating the immune system. 
Concluding remarks 
Gut commensal bacteria produce a myriad of microbial metabolites. These metabolites function 
as nutrients and/or activate host receptors, including GPR43, GPR41, GPR109A, PXR, FXR, and 
TGR5. While not discussed in detail, P2X receptors (P2X1-7) are expressed by many cell types 
including tissue, myeloid, mast, and T cells to sense ATP 130, which is produced by both host and 
microbial cells. Activation of P2X7, for example, leads to Ca2+ influx and subsequent 
inflammasome activation or cell death for positive and negative regulation of the immune 
system 131-133. The host receptors for microbial metabolites are expressed by diverse cell types in 
barrier and systemic tissues. Therefore, gut microbial metabolites and their receptors create an 
extensive array of signaling to sense and respond to nutritional status and host conditions 
reflected in microbial activity. It is apparent that gut microbial metabolites can promote both 
immunity and tolerance, both of which are required to maintain health by preventing chronic 
infection and inflammatory diseases. Microbial metabolites strengthen barrier tissues and train 
the immune system to prevent and prepare for possible infection by pathogens. Beyond the 
immune system, gut metabolites and their receptors maintain homeostasis of metabolism, which 
is important to maintain host health by balancing nutrients intake and utilization. Diseases and 
pathological conditions cause gut dysbiosis and altered production of microbial metabolites, 
leading to dysregulation of the immune system and metabolism. More research is required to 
identify the immune regulatory functions of individual metabolites in health and disease. More 
importantly, how these microbial metabolites in combination regulate the host immune system 
remains to be elucidated. Furthermore, how altered composition of microbial metabolites is 
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associated with specific diseases should be studied in an effort to identify biomarkers for 
pathological conditions. 
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Figure legends 
 
Figure 1. Production of microbial metabolites and their major receptors in the immune system. 
The gut microbiota can metabolize a variety of dietary materials, which include carbohydrates, 
proteins, lipids, plant-derived molecules, bile acids, and environmental contaminants. These 
materials are metabolized into SCFAs, polyamines, ATP, indoles, phytochemical metabolites, 
and bile acid metabolites. SCFAs function as HDAC inhibitors to regulate gene expression and 
activate GPCRs such as GPR43, GPR41, GPR109A (C4), and Olfr78 (C3). Other metabolites 
collectively activate nuclear receptors (AhR, PXR, VDR, LXR, and FXR), TGR5, and P2XRs. 
These receptors are expressed by various cells in the innate and adaptive immune systems to 
sense the presence of the gut microbial metabolites.  
 
 Figure 2. Impacts of microbial metabolites on the immune system. Gut microbial metabolites 
exert far-reaching influences on the host. They regulate the immune system through HDACs, 
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receptors and/or metabolic integration. SCFAs fuel and fortify epithelial cells for promoting 
barrier functions. SCFAs also function as a neutrophil chemotaxin and regulate macrophages and 
dendritic cells through GPCRs and HDACs. Bile acid metabolites also induce tolerogenic DCs 
and type 2 macrophages (M2), effects mediated by multiple receptors. AhR activation by gut 
microbial metabolites induce regulatory T cells that express FoxP3 and IL-10. Many gut 
microbial metabolites support the generation of induced Tregs for immune tolerance. SCFAs 
also fuel B cells and promote their differentiation into IgA or IgG-producing plasma B cells, an 
effect mediated by HDAC inhibition and metabolic regulation by SCFAs. However, during 
infection, gut microbial metabolites promote the generation of effector T cells such as Th1 and 
Th17 cells to fight pathogens. P2X7 activation by ATP and NAD exert both positive and 
negative regulatory roles in the immune system. Both tolerogenic and inflammatory functions of 
gut microbial metabolites have been reported, indicating that the overall functions of gut 
microbial metabolites are determined by the immune status of the host. 
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